News on improved reading ability in new published trial 2017
Dr Mats Johnson presents Equazen eye q clinical trial at Swiss Neuro-paediatrics Association annual meeting showing improved reading ability.
Omega-3 and omega-6 fatty acids are important membrane components of the brain. Accumulating evidence from epidemiological, biochemical and intervention studies indicate that suboptimal dietary intake of omega-3 and omega-6 fatty acids can have detrimental effects on children’s cognitive development and behaviour.
A recent randomised, double-blind, placebo-controlled trial in 9-year-old mainstream schoolchildren in Sweden was conducted to evaluate the effect of Omega 3/6 fatty acids on reading in children.
The study, known as the LOGOS trial has been presented by its author, Dr. Johnson, at the the annual meeting of Swiss Neuro-paediatrics Association, Solothurn, Switzerland.
Over 150 Doctors, mainly Neuropsychiatric specialists and Paediatricians, attended the 2- day meeting.
The study was conducted on 154 children over a period of 6 months on 2 phases of 3 months each, and the outcomes measured the Logos test battery which is a computerised reading test based on the theory that word decoding is a central function for reading ability.
Results have shown that Equazen eye q significantly improves reading ability, naming time, phonologic decoding time, visual analysis time, reading speed per word and phonologic decoding time per word when compared to placebo.
The study showed that:
- eye q improves reading ability in mainstream schoolchildren
- eye q is well tolerated and has a high compliance similar to that of placebo